News

Board reiterates recommendation that shareholders vote FOR the transaction with Sterigenics OTTAWA, Ontario–(BUSINESS WIRE)–May 9, 2014– Nordion Inc. (TSX:NDN) (NYSE:NDZ) today announced that it has filed a supplement (the “Supplement”) to its management information circular dated April 22, 2014. The Supplement contains detailed information as…

OTTAWA, Ontario–(BUSINESS WIRE)–Apr. 1, 2014— Nordion Inc. (TSX:NDN) (NYSE:NDZ), announced today that the Ontario Superior Court of Justice has granted an order extending the time for calling and holding the Company’s annual general meeting (the “AGM“), which was scheduled to take place on April 29,…

Transaction successfully completes Nordion’s strategic review, subject to closing, delivering value to shareholders Shareholders to receive an aggregate cash consideration of US $11.75 per share Nordion to hold conference call and webcast at 8:00 am ET on Monday, March 31, 2014 to discuss the announcement…

Industry leaders hear about the latest irradiation developments at IMRP 2013

OTTAWA, Ontario–(BUSINESS WIRE)–Nov. 4, 2013Nordion, a leading supplier of Cobalt-60 and a global leader in the design and construction of commercial gamma irradiation systems, today joins the International Irradiation Association (iiA) and other industry leaders at the 2013 International Meeting on Radiation Processing (IMRP) in Shanghai, China…

Capability Opens New Market Opportunities to Ultra-Low Power Memory Products

OTTAWA, Canada–(BUSINESS WIRE)–Oct. 16, 2013Adesto Technologies, a memory solutions provider delivering innovative products for code and data storage applications, and Nordion, with global expertise in the design and construction of commercial gamma irradiation systems, today announced the successful completion of gamma irradiation testing of Adesto’s CBRAM non-volatile memory products…

OTTAWA, Ontario–(BUSINESS WIRE)–Jul. 15, 2013 — Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced that it has completed the divestiture of its Targeted Therapies business to BTG plc (LSE: BTG), an international specialist healthcare company based in London, United Kingdom for a cash purchase price of US$200 million…